COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC) (PSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03041662
Recruitment Status : Completed
First Posted : February 3, 2017
Last Update Posted : February 3, 2017
Information provided by (Responsible Party):
Annika Bergquist, Karolinska University Hospital

Brief Summary:
This observational study of a national cohort of 600 Swedish PSC patients include yearly MR/MRCP, biobanking of serum, plasma and blood, followup clinical data (interventions, symptoms, labs, colonoscopy). The aim is to collect a well characterized cohort of PSC patients and provide future possibilities to evaluate biomarkers for prognosis and early cancer detection.

Condition or disease Intervention/treatment
Primary Sclerosing Cholangitis Cholangiocarcinoma Diagnostic Test: MR/MRCP

Layout table for study information
Study Type : Observational
Actual Enrollment : 620 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Actual Study Start Date : October 31, 2011
Actual Primary Completion Date : October 31, 2016
Actual Study Completion Date : October 31, 2016

Intervention Details:
  • Diagnostic Test: MR/MRCP

Primary Outcome Measures :
  1. cholangiocarcinoma [ Time Frame: 10 yrs f-up ]
  2. liver transplatation [ Time Frame: 10 yrs f-up ]
  3. death [ Time Frame: 10 yrs f-up ]

Secondary Outcome Measures :
  1. biliary dysplasia [ Time Frame: 10 yrs f-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
National Swedish cohort of PSC patients followed at 14 hospitals

Inclusion Criteria:

  • Diagnosis of PSC by MR/MRCP
  • Life expectancy >1 year
  • Informed consent

Exclusion Criteria:

  • Liver transplantation or on the waiting list
  • Secondry SC
  • Diagnosis of CCA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03041662

Layout table for location information
Karolinska University Hospital, Huddinge
Stockholm, Sweden, 14186
Sponsors and Collaborators
Karolinska University Hospital
Layout table for additonal information
Responsible Party: Annika Bergquist, professor, Karolinska University Hospital Identifier: NCT03041662    
Other Study ID Numbers: 2011/2:6
First Posted: February 3, 2017    Key Record Dates
Last Update Posted: February 3, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases